Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
About this item
Full title
Author / Creator
Eskander, Ramez N. , Sill, Michael W. , Beffa, Lindsey , Moore, Richard G. , Hope, Joanie M. , Musa, Fernanda B. , Mannel, Robert , Shahin, Mark S. , Cantuaria, Guilherme H. , Girda, Eugenia , Mathews, Cara , Kavecansky, Juraj , Leath, Charles A. , Gien, Lilian T. , Hinchcliff, Emily M. , Lele, Shashikant B. , Landrum, Lisa M. , Backes, Floor , O’Cearbhaill, Roisin E. , Al Baghdadi, Tareq , Hill, Emily K. , Thaker, Premal H. , John, Veena S. , Welch, Stephen , Fader, Amanda N. , Powell, Matthew A. and Aghajanian, Carol
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.
Alternative Titles
Full title
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Authors, Artists and Contributors
Author / Creator
Sill, Michael W.
Beffa, Lindsey
Moore, Richard G.
Hope, Joanie M.
Musa, Fernanda B.
Mannel, Robert
Shahin, Mark S.
Cantuaria, Guilherme H.
Girda, Eugenia
Mathews, Cara
Kavecansky, Juraj
Leath, Charles A.
Gien, Lilian T.
Hinchcliff, Emily M.
Lele, Shashikant B.
Landrum, Lisa M.
Backes, Floor
O’Cearbhaill, Roisin E.
Al Baghdadi, Tareq
Hill, Emily K.
Thaker, Premal H.
John, Veena S.
Welch, Stephen
Fader, Amanda N.
Powell, Matthew A.
Aghajanian, Carol
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10351614
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10351614
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2302312
